Zealand Pharma's CEO Adam Steensberg weighs in on early-stage trials of its obesity drug contender and talks down takeover ...
A CNBC investigation into illegal weight loss drugs reveals a marketplace where criminals brazenly counterfeit the drugs or ...
The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's ...
Therapies that deliver hydrogen sulfide to cells could one day become the basis of new treatments for obesity and related ...
The FDA decision will enable Antag Therapeutics to initiate the clinical development of its lead candidate drug, a ...
A review of the recent evidence suggests that GLP-1 drugs, such as semaglutide, could protect brain health and cognitive ...
Allowing Medicare to cover anti-obesity medications would drive up federal spending by about $35 billion on net between 2026 and 2034, according to ...
France is the latest European country to refuse to cover weight loss drugs through its national insurance programme.
Medicare is prohibited by law from covering GLP-1 drugs for weight loss. But many beneficiaries can access the drugs anyway.
News Medical on MSN2h
New nanoparticle system fights obesityResearchers have unveiled a novel approach to tackle obesity by targeting fat absorption in the small intestine. The ...
John M. Burke, MD, examines how new obesity treatments, such as GLP-1 agonists, might influence future cancer rates.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback